Page last updated: 2024-11-12
zabofloxacin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
zabofloxacin: a fluoroquinolone antibiotic [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10388396 |
| CHEMBL ID | 2107811 |
| SCHEMBL ID | 2985495 |
| MeSH ID | M0458482 |
Synonyms (12)
| Synonym |
|---|
| dw-224a |
| zabofloxacin |
| 219680-11-2 |
| CHEMBL2107811 |
| zabofloxacin [who-dd] |
| SCHEMBL2985495 |
| 1-cyclopropyl-6-fluoro-7-[(8z)-8-methoxyimino-2,6-diazaspiro[3.4]octan-6-yl]-4-oxo-1,8-naphthyridine-3-carboxylic acid |
| Q17143544 |
| CS-0025745 |
| HY-106410 |
| gtpl10873 |
| AKOS040740615 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " The absolute toxic dose of DW-224a was 30 mg/kg and the level at which no adverse effects were observed was 10 mg/kg for both sexes." | ( Subacute toxicity and toxicokinetics of a new antibiotic, DW-224a, after single and 4-week repeated oral administration in dogs. Choi, DR; Chung, MK; Han, J; Kim, B; Kim, JC, 2003) | 0.32 |
| " Our data suggested that DW-224a showed no adverse effects on the central nervous system, cardiovascular system, and respiratory system, with the exception of the effect on the QT interval prolongation." | ( Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent. Han, SS; Kim, EJ; Kim, KS; Shin, WH, 2004) | 0.32 |
Pharmacokinetics
The applicability of the developed assay method to pharmacokinetic studies of zabofloxacin in rats was examined.
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The bioavailability of zabofloxacin was 27." | ( Fluorescence detection of Zabofloxacin, a novel fluoroquinolone antibiotic, in plasma, bile, and urine by HPLC: the first oral and intravenous applications in a pharmacokinetic study in rats. Jin, HE; Kang, IH; Shim, CK, 2011) | 0.98 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " The maximum plasma concentrations (Cmax), the area under the plasma concentration versus time curve (AUC) from the time of dosing to 48 hours post-dosing (AUClast), and the AUC extrapolated to infinity (AUCinf) were determined from the plasma concentration-time profile." | ( Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet. Cho, JY; Han, H; Kim, SE; Lim, C; Lim, KS; Shin, KH; Yu, KS, 2013) | 0.62 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (15)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 24.88
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.88) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (18.75%) | 5.53% |
| Reviews | 1 (6.25%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||